Kyriakie Sarafoglou1, Gregory P Forlenza2, O Yaw Addo3, Jennifer Kyllo4, Aida Lteif5, P C Hindmarsh6, Anna Petryk1, Maria Teresa Gonzalez-Bolanos1, Bradley S Miller1, William Thomas7. 1. Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA. 2. Pediatric Endocrinology Barbara Davis Center, University of Colorado Denver, Denver, CO, USA. 3. Global Health, Rollins School of Public Health of Emory University, Atlanta, GA, USA. 4. Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, USA. 5. The Mayo Clinic College of Medicine, Rochester, MN, USA. 6. Institute of Child Health, University College London, London, UK. 7. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Abstract
OBJECTIVES: To evaluate obesity and overweight in children with congenital adrenal hyperplasia (CAH) and associations with glucocorticoids, fludrocortisone and disease control. Adjusting body mass index-for-height-age (BMIHA ) percentile is proposed to correct misclassification of obese/overweight status in CAH children with advanced bone age and tall-for-age stature. DESIGN: Longitudinal. PATIENTS: One hundred and ninety-four children with CAH seen from 1970 to 2013: 124 salt wasting (SW); 70 simple virilizing (SV); 102 females. MEASUREMENTS: Body mass index (BMI) end-points were overweight (85-94 percentile) and obese (≥95 percentile). RESULTS: Approximately 50% of the children had at least one BMI measurement ≥95 percentile and about 70% had at least one ≥85 percentile. Using BMIHA percentiles, obesity incidence decreased slightly in SW children (47-43%) and markedly in SV children (50-33%); however, overweight status was not reduced. Only 6% of SW and 1% of SV children were persistently obese (≥3 clinic visits) when BMIHA was applied, whereas overweight status persisted in 35% of SW and 33% of SV children. Most obesity or overweight when using BMIHA occurred before age 10 and there was no association with hydrocortisone (HC) or fludrocortisone dosing. Adiposity rebound for SW children occurred by 3·3 years and in SV females by age 3·8 years, over a year earlier than the adiposity rebound for healthy children. CONCLUSION: Children with CAH are at higher risk for early onset obesity and overweight with or without using BMIHA but rates of persistent obesity were lower than previously reported. Careful HC dosing during early childhood is needed to prevent increased weight gain and an early adiposity rebound.
OBJECTIVES: To evaluate obesity and overweight in children with congenital adrenal hyperplasia (CAH) and associations with glucocorticoids, fludrocortisone and disease control. Adjusting body mass index-for-height-age (BMIHA ) percentile is proposed to correct misclassification of obese/overweight status in CAH children with advanced bone age and tall-for-age stature. DESIGN: Longitudinal. PATIENTS: One hundred and ninety-four children with CAH seen from 1970 to 2013: 124 salt wasting (SW); 70 simple virilizing (SV); 102 females. MEASUREMENTS: Body mass index (BMI) end-points were overweight (85-94 percentile) and obese (≥95 percentile). RESULTS: Approximately 50% of the children had at least one BMI measurement ≥95 percentile and about 70% had at least one ≥85 percentile. Using BMIHA percentiles, obesity incidence decreased slightly in SW children (47-43%) and markedly in SV children (50-33%); however, overweight status was not reduced. Only 6% of SW and 1% of SV children were persistently obese (≥3 clinic visits) when BMIHA was applied, whereas overweight status persisted in 35% of SW and 33% of SV children. Most obesity or overweight when using BMIHA occurred before age 10 and there was no association with hydrocortisone (HC) or fludrocortisone dosing. Adiposity rebound for SW children occurred by 3·3 years and in SV females by age 3·8 years, over a year earlier than the adiposity rebound for healthy children. CONCLUSION:Children with CAH are at higher risk for early onset obesity and overweight with or without using BMIHA but rates of persistent obesity were lower than previously reported. Careful HC dosing during early childhood is needed to prevent increased weight gain and an early adiposity rebound.
Authors: Mimi S Kim; Anna Ryabets-Lienhard; Anh Dao-Tran; Steven D Mittelman; Vicente Gilsanz; Sheree M Schrager; Mitchell E Geffner Journal: J Clin Endocrinol Metab Date: 2015-06-10 Impact factor: 5.958
Authors: Gabriela P Finkielstain; Mimi S Kim; Ninet Sinaii; Miki Nishitani; Carol Van Ryzin; Suvimol C Hill; James C Reynolds; Reem M Hanna; Deborah P Merke Journal: J Clin Endocrinol Metab Date: 2012-09-18 Impact factor: 5.958
Authors: Kyriakie Sarafoglou; Cheryl L Zimmerman; Maria T Gonzalez-Bolanos; Brian A Willis; Richard Brundage Journal: J Investig Med Date: 2015-01 Impact factor: 2.895
Authors: Eric M Bomberg; O Yaw Addo; Jennifer Kyllo; Maria T Gonzalez-Bolanos; Aida M Ltief; Siobhan Pittock; John H Himes; Bradley S Miller; Kyriakie Sarafoglou Journal: J Pediatr Date: 2014-12-31 Impact factor: 4.406
Authors: S Péneau; R González-Carrascosa; G Gusto; D Goxe; O Lantieri; L Fezeu; S Hercberg; M F Rolland-Cachera Journal: Int J Obes (Lond) Date: 2016-03-22 Impact factor: 5.095
Authors: Adnan Al Shaikh; Yasser AlGhanmi; Saniah Awidah; Abdullah Bahha; Mohamed E Ahmed; Ashraf T Soliman Journal: Indian J Endocrinol Metab Date: 2019 May-Jun
Authors: Richard J Auchus; Kyriakie Sarafoglou; Patricia Y Fechner; Maria G Vogiatzi; Erik A Imel; Shanlee M Davis; Nagdeep Giri; Julia Sturgeon; Eiry Roberts; Jean L Chan; Robert H Farber Journal: J Clin Endocrinol Metab Date: 2022-02-17 Impact factor: 5.958
Authors: Gagandeep Bhullar; Veeraya K Tanawattanacharoen; Mei Y Yeh; William S Kim; Alaina P Vidmar; Mitchell E Geffner; Darryl H Hwang; Mimi S Kim Journal: Horm Res Paediatr Date: 2021-03-10 Impact factor: 2.852